Edition:
India

People: Kazia Therapeutics Ltd (KZIA.OQ)

KZIA.OQ on NASDAQ Stock Exchange Capital Market

3.14USD
17 Sep 2018
Change (% chg)

-- (--)
Prev Close
$3.14
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
3,845
52-wk High
$6.64
52-wk Low
$2.28

Leong, Peng 

Mr. Peng K. Leong is the Chief Business Officer of the Company. Dr Peng Leong will join the company as Chief Business Officer, commencing in September. Dr Leong will be primarily responsible for identifying and negotiating in-licensing and out-licensing opportunities for Novogen, and will take a central role in the ongoing development and execution of Novogen's corporate strategy. Dr Leong has spent eighteen years in the pharmaceutical industry, beginning as a scientist, and followed by eight years in healthcare investment banking and private equity, and eight years in business development. Dr Leong started his career at Chiron Corporation, a pioneering biotechnology company based in California that was subsequently acquired by Novartis International AG (NYSE: NVS). While working in healthcare investment banking at CIBC World Markets and Piper Jaffray, he was involved in raising more than US$ 1.4 billion for over 20 biotechnology companies. In his various roles, including his most recent position at Merck Serono (FWB: MRK), Dr Leong has had a leadership role in the acquisition or sale of over US$ 1 billion in pharmaceutical product rights. He holds a PhD in Biochemistry from the University of Toronto, Canada and an MBA from the University of California, Berkeley. Dr Leong will be based in Cambridge, Massachusetts. In addition to these senior management appointments, Novogen has bolstered its operational capabilities by hiring David Cain, formerly of Aviragen Therapeutics Inc (NASDAQ: AVIR), previously known as Biota Pharmaceuticals. Mr Cain will join Novogen as Director of Chemistry, Manufacturing, and Controls (CMC) and will commence work with the company in October.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --